secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-08-05T20:09:55+00:00
Accession:  0001628280-26-053351
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology Q2 net income $80.1M on Astellas deal; cash $1.01B
--------------------------------------------------------------------

- Net income of $80.1M ($0.48 diluted EPS) vs net loss of $111.0M in Q2 2025.
- Revenue $238.9M, primarily from $240M Astellas upfront payment; cash $1.01B.
- Phase 2 SOLSTICE: 88% of CHD patients achieved undetectable HDV RNA at Week 96.
- Phase 3 ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2 fully enrolled.
- Appointed Timothy Coughlin to Board and as Audit Committee Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/0001628280-26-053351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/vir-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer